Skip to search formSkip to main contentSkip to account menu

ZD 9331

Known as: BGC 9331, ZD9331, ZD-9331 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Antineoplastic AgentsQuinazolines
Plevitrexedtopotecan/ZD9331

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Targeted Thymidylate Synthase Inhibitor BGC 945 −-Folate Receptor α Imaging Pharmacodynamics of the Updated
The assessment of tissue-specific pharmacodynamics is desirable in the development of tumor-targeted therapies. Plasma… 
2006
2006
The Critical Role of Polyglutamylation Reductase and Inhibitors of Other Folate-requiring Enzymes : Synergy between Inhibitors of Dihydrofolate in Vitro Super Updated
The combined action among polyglutamylatable and nonpolyglutamylatable antifolates, directed against dihydrofolate reducÃ-ase… 
Review
2005
Review
2005
ZD9331: discovery to clinical development
Thymidylate synthase (TS) has been targeted in cancer therapy for many years. As a result of a prolonged and extensive drug… 
2004
2004
P 21 Cip 1 Is a Critical Mediator of the Cytotoxic Action of Thymidylate Synthase Inhibitors in Colorectal Carcinoma Cells
  • 2004
  • Corpus ID: 28138272
We have demonstrated previously that interferon (IFN)sensitizes human colon carcinoma cell lines to the cytotoxic effects of 5… 
2004
2004
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
Purpose: To assess the feasibility of administering ZD9331, a thymidylate synthase (TS) inhibitor that does not undergo… 
1998
1998
Phase I trial of ZD9331 given as a 30 minute infusion on days 1 and 8 with cycles repeated every 3 weeks
1998
1998
Evidence for the duration of the antifolate action of the thymidylate synthase (TS) inhibitor ZD9331 using plasma dUrd as a surrogate marker of enzyme inhibition
1998
1998
Plasma 2 '-deoxyuridine (dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in patients in phase I clinical trials of the TS inhibitor ZD9331
1997
1997
Interference by antifolate drugs in a folate competitive protein-binding assay
Thymidylate synthase (TS, EC 2.1.1.45) and other folatedependent enzymes have recently received much interest as chemotherapeutic… 
Review
1996
Review
1996
Section Review: Oncologic, Endocrine & Metabolic: The new generation of thymidylate synthase inhibitors in clinical study
In the last five years, six new antifolate drugs, all targeted towards thymidylate synthase (TS), have entered clinical studies… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)